Astrolabe Analytica Announces Study on New Therapeutic Area: Meningitis Vaccines.

Business Editors/Health/Medical Writers

PHILADELPHIA--(BUSINESS WIRE)--June 9, 2003

Astrolabe Analytica, Inc.

With a fatality rate approaching 10 percent, and the potential

for resistance to antibiotics growing, the need for improved

meningitis vaccines is becoming imperative.

A new subscription service in the area of Meningitis Vaccines has been announced by Astrolabe Analytica, Inc.

The company is using its ASTROLABE Message Mapping System(TM) to perform both archival and on-going analyses of material published in professional and trade media to help pharmaceutical and biologics companies, and medical device manufacturers keep abreast of developments in the field of vaccines as they relate to meningococcal bacterial infections. The ongoing analyses assess key developments as they are reported, and review archival files of material published over the last eight years.

"This is the 11th therapeutic area of study that we have opened to subscribers," said Lawrence Liberti, executive vice president of Astrolabe Analytica, in making the announcement. "For each therapeutic area, we use our ASTROLABE Message Mapping System to view the history of developments in the field. These analyses help our clients determine how clinical trials of their products may complement the body of knowledge that already exists. These analyses are unique in that they are presented from both a rigorous scientific perspective and also from the perspective of the prescribing health professional."

Each therapeutic area analyzed by the ASTROLABE Message Mapping System is updated on a monthly basis. "The information is reviewed and analyzed as it comes in, and is made available to subscriber personnel throughout the world via a secure web site," added Liberti.

"Almost 10 percent of the general population harmlessly carry the bacteria that cause meningococcal disease at any given time. During an outbreak of the disease, this number can jump to as high as 95 percent. Analyzing and studying research findings as they are published in the field of meningitis vaccines are critically important because, during an outbreak, almost one percent of the people carrying the disease may become infected, while the potential for resistance to antibiotics to combat the disease is growing."

Developments in the area of meningitis are extremely important to those pharmaceutical and drug delivery companies that constantly chart the latest data and research on this disease.

They will look to the ASTROLABE Message Mapping System analysis of Meningitis Vaccines to provide an on-going survey of developments in the area, and then use the findings to identify the best means of communicating the results of clinical trials to the medical community. "The benefits of our on-going ASTROLABE Message Mapping analyses will cascade throughout their companies," concluded Liberti, "to people in different functional areas and even groups throughout the world."

Other therapeutic areas currently being monitored by Astrolabe Analytica include:

-- Glaucoma 

-- Osteoporosis 

-- Antihistamines 

-- Asthma

-- Nasal anti-inflammatories

-- Anti-fungals (systemic infections)

-- Diabetes

-- Anticoagulants 

-- Acne 

-- Onychomycosis

Further information about Astrolabe Analytica, Inc., its ASTROLABE Message Mapping System, and its on-going subscriber studies can be obtained by writing to: Astrolabe Analytica, Inc., 3701 Market Street, Suite 340, Philadelphia, PA 19104, calling 215-966-6222 or visiting the web site www.AstrolabeAnalytica.com.